Both conventional chimerism analysis (CCA) and lineagespecific chimerism analysis (LCA) have potential pitfalls as diagnostic means for the detection of minimal residual disease after allogeneic hematopoietic cell transplantation (aHCT). Therefore, the present study examines the results of both methods in order to determine how predictive consecutive evaluations were, with respect to the risk that the patient would relapse during post-transplant follow-up and with respect to responsiveness to immunomodulatory treatment. A total of 168 individuals with acute myeloid leukemia (AML) (n ¼ 137) and myelo dysplastic syndrome (n ¼ 31) were investigated with CCA and LCA at mean intervals of 24 days (range: 11-116). The median follow-up after myeloablative aHCT was 22 months (range: 4-49). Of 168 patients, 65 experienced a clinical relapse after aHCT. CCA and LCA were comparatively sensitive and specific for relapse at the intervals of chimerism testing employed in this study. Of 32 patients, 10 who were offered donor lymphocyte infusions (DLI) treatment for increasing (n ¼ 29) or stable (n ¼ 3) mixed chimerism (MC) achieved at least transitory CC. The observation that all patients with increasing MC relapsed despite DLI treatment (54%) or withdrawal of immune suppression (24%) indicates that novel strategies to deal with rapidly evolving relapse in AML patients, such as shortening of chimerism monitoring intervals, need to be evaluated.
Introduction
Allogeneic hematopoietic cell transplantation (aHCT) is a curative treatment option for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), but relapse remains the most frequent cause of treatment failure. 1 CML patients receiving donor lymphocyte infusions (DLI) after the detection of a molecular or cytogenetic relapse have responded better than patients treated after hematological relapse. 2, 3 This indicates the clinical relevance of early detection of minimal residual disease (MRD). After withdrawal of immunosuppression and DLI, monitoring of chimerism kinetics may facilitate decision making for additional doses.
In acute leukemias and MDS, early detection of patients at risk of a threatening relapse followed by DLI may prevent a hematological relapse. 4 Mixed chimerism (MC) may be an indicator of immunotolerance between donor and recipient tissue, and may indicate an impaired graft-versus-leukemia (GVL) effect that has been demonstrated to be relevant for the therapeutic success of aHCT in several hematological malignancies. [5] [6] [7] [8] However, the occurrence of a constantly low MC in the peripheral blood (PB) or bone marrow (BM) after aHCT may not always predict relapse and is influenced by several factors including the conditioning regimen, the graft-versus-host disease (GVHD) prophylaxis and the graft. A low dose of total body irradiation and T-cell depletion are associated with a higher incidence of autologous marrow repopulation and, consecutively, a higher rate of MC. 9, 10 To improve the predictive value of chimerism monitoring for relapse, the immunophenotype of the original leukemic clone can be used for enrichment of distinct malignant cell populations within the investigated sample. [11] [12] [13] The current availability of lineage-specific chimerism analysis (LCA) in addition to conventional chimerism analysis (CCA) has led to a more frequent application of this method to evaluate the presence of MC. However, there is little data about whether or not LCA can improve the diagnostic information for patients with malignant disease after aHCT as compared to CCA. Therefore, the aim of the present study was to compare the results of LCA and CCA in order to determine their sensitivity and specificity for the detection of MRD in AML and MDS patients undergoing myeloablative conditioning and aHCT. Furthermore, CD3
þ subsets for T-cell chimerism were evaluated with respect to conventional chimerism monitoring, morphological examination, relapse and the occurrence of GVHD.
Patients, materials and methods

Patients
Between January 18, 1999 and July 30, 2004 , 168 individuals with AML (n ¼ 137) and MDS (n ¼ 31) were prospectively evaluated for MC at the Stem Cell Transplantation Ward at the Department of Hematology and Oncology, Freiburg University Medical Center, with a median follow-up of 22 months (range: 4-49). For the detection of MC, both CCA and LCA were applied. The studies were carried out according to the guidelines of the Declaration of Helsinki and according to good clinical practice after informed consent. All chimerism results were documented with respect to indication (clinical suspicion of relapse as opposed to routine examination), date and test result. The median percentage of CD34 þ blasts in BM at diagnosis was 56% (33-85%) and 11% (4-18%) in AML and MDS patients, respectively.
Conditioning regimens and grafts
Conditioning regimens included busulfan (4 mg/kg/day for 4 days) and cyclophosphamide (60 mg/m 2 /day for two days) (BuCy), in 73 patients. 14 In all, 95 patients received a myeloablative, reduced-intensity conditioning (FBM) with fludarabine (30 mg/m 2 for 5 days), carmustine (150 mg/m 2 for 2 days) and melphalan (110 mg/m 2 for 1 day) as described previously. 15 Patients were transplanted with unmodified peripheral blood stem cells (n ¼ 156) or BM (n ¼ 12). A total of 67 patients received aHCT from HLA-identical siblings, 86 from HLA-A-, HLA-B-, HLA-DQB1 n -and/or HLA-DRB1 n -compatible unrelated donors (MUD) and 15 from HLA-A-, HLA-B-, HLA-DQB1 n -and/or HLA-DRB1 n -mismatched donors. HLA-class I typing was performed serologically and class II typing was performed at the molecular level.
Definition of remission and relapse
Patients were analyzed routinely with the examination of the morphology of BM aspirates and biopsies at days 30, 100 and 365 for MDS patients achieving CC on day þ 30 post aHCT. In accordance with the individual risk profile, additional examinations were performed in monthly intervals in MDS patients with MC and AML patients. BM smears were investigated at the hematology laboratory by at least two experienced physicians, flow-cytometry analysis was performed at the immunocytology laboratory at the Freiburg University Medical Center.
A patient was considered to be in clinical remission when less than 6% blast cells were found in a BM sample upon morphological examination. Hematological relapse was defined as having at least 6% blast cells in BM aspirates or the presence of extramedullary leukemic cells (extramedullary relapse (EMR)). In MDS type RAEB or RAEB-t patients relapse was defined according to the guidelines of the WHO classification. 16 Clinical relapse was defined as at least two consecutive BM examinations demonstrating 45% blasts within an interval of at least 2 weeks. Examinations were performed due to clinical suspicions vs those carried out for routine use in order to satisfy the institutional chimerism testing protocol.
Chimerism assays and cell separation
MDS patients achieving CC at day þ 30 were additionally investigated for MC at days þ 100 and þ 365 post-aHCT. Conversely, MDS patients not achieving CC at day þ 30 and standard risk AML patients were tested in monthly intervals. In the presence of high-risk factors, including secondary AML, unfavorable cytogenetics, primary induction failure or 4CR1, AML patients were followed with chimerism monitoring semimonthly for the first year and then every other month for the second year. Beyond the second year, most patients received chimerism monitoring at 3-4 months intervals.
MC was defined as detectable donor and recipient DNA in a post-transplant sample and depended on the individual sensitivity of the applied marker.
Patients with MC were monitored at least once per week. Chimerism kinetics were divided into decreasing MC (spontaneous decreases over time), stable MC (continuous donor and recipient chimerism) and increasing chimerism (an increase in recipient DNA as compared to the previous investigation by at least 5%).
In patients with MC, the pattern of chimerism was determined by at least two independent tests in weekly intervals. Patients with a weak autologous signal (o5%) or signals that were not confirmed by repeated analysis 1 week later were defined as having a low-level MC (LL-MC) as compared to all others.
Prior to separation, samples were screened for an aberrant leukemia immunophenotype other than CD34 by flow cytometry (FACS Calibur, BD, Heidelberg, Germany). In the absence of CD34, patients were monitored by CCA, BME, molecular markers and cytogenetics only and were not included in the present study. Cells were purified by positive selection of CD34 þ and CD3 þ cells using the Auto-MACS magnetic cell sorting system (Miltenyi, Bergisch-Gladbach, Germany) according to the manufacturer's protocol and all magnetically labeled antibodies were purchased from Miltenyi. To increase purity, the separation was repeated at least twice. Purity testing was performed with phycoerythrin (PE)-labeled antibodies against human CD3 and CD34 (Immunotech, Marseille, France). Samples with a purity below 90% were excluded.
Immunotherapy
The standard measures taken in response to increasing MC are DLI, if possible. The first dose of DLI is given as soon as available. In case of further increase after DLI, additional infusions are performed after an interval of at least 2 weeks. Reasons not to receive DLI despite increasing MC are active GVHD, unavailable matched unrelated donor for leukapheresis or early hematological relapse. In the latter group, we aim for a second aHCT. In case of increasing MC, despite withdrawal of immunosuppression, DLI are offered with respect to GVHD severity. Patients with stable MC do not receive DLI routinely, but with respect to their risk factors for relapse. Stable MC is considered as an indication to withdraw immunosuppression. Immunotherapy for patients not receiving immunosuppression consisted of DLI with or without interferon (IFN)-a or interleukin (IL)-2 as front-line treatment. The T-cell dose employed was based on the number of HLA mismatches and the presence and severity of GVHD. A response to cessation of immunosuppression/DLI was defined as a return to CC in PB and/or BM.
DNA preparation protocol
Genotyping for the detection of informative STR loci was usually performed using 10 ml EDTA PB from the recipient and from the donor. The Qiagen DNA Blood Kit (Qiagen, Hilden, Germany) was used according to the manufacturer's instructions. For DNA extraction from o500 cells/ml, 500-2000 cells/ml and 2000-5000 cells/ml, 22, 30 and 50 ml of elution buffer were used, respectively. The DNA yield was quantified by spectrophotometry and 10-50 ng of DNA were used as template in individual PCR reactions.
PCR methods and markers
The PCR reactions for patient/donor genotyping and follow-up of chimerism post-transplant included: 1.4 Â buffer (15 mM MgCl 2 ), 200 M dNTPs, 5 pmol of each primer 1 U HotStar Taq polymerase (Qiagen, Hilden, Germany) in a final volume of 20 ml. PCR reactions containing DNA derived from mononuclear cells (MNCs) were performed in a final volume of 50 ml to permit inclusion of a larger DNA template volume. The applied 5-FAM-labeled markers were: SE33, THO-1, D1S80, D14S120 and YNZ22 as detailed in Table 1 . [17] [18] [19] [20] [21] To screen for an informative marker that enabled distinctive discrimination between recipient and donor, genomic DNA was amplified by PCR.
Analysis of PCR products
PCR products were analyzed by capillary electrophoresis (ABI Prism 310 Genetic Analyzer, Foster City, CA, USA). Fragments were quantified using the Genescan 2.1 and 3.1 software (Applied Biosystems).
PCR sensitivity determination within mixed chimeric samples by limiting dilution assays for CCA and LCA PB samples from healthy donors and myeloid leukemic cells expressing CD34 (Kasumi-3) were collected and the informative STR marker was determined. In order to simulate different clinical situations post-aHCT with a cellular dilution series, normal cells of an individual A were diluted in whole EDTA blood with a known total WBC of individual B. For LCA sensitivity testing, CD34 þ leukemic cells were diluted within normal blood with a known total WBC of a different individual and afterwards purified with immunomagnetic beads. For sensitivity calculation, the following serial dilution was applied: 20, 10, 5, 4, 3, 2, 1, 0.5, 0.1, 0.05 and 0.01%. The in vitro sensitivity of the different markers with respect to the applied method (CCA vs LCA) are depicted in Table 1 (average from at least three independent experiments).
Statistical analysis
Relapse and non-relapse mortality (NRM) were considered to be competing risks and the probabilities of relapse or NRM were estimated as cumulative incidence rates as previously described. 22 The cumulative relapse incidence in the donor and mixed chimeric groups was calculated as described previously. 22 Nonrelapse mortality was separately investigated for the CC and the MC subgroups. The sensitivity and specificity were calculated as described previously. 23 Clinical relapse, as defined by repeated BME, was considered to be the gold standard. Exact 95% confidence intervals (CI's) were derived from the binomial distribution. Statistical significance was defined as Po0.05.
Results
Patients
All patients included in this study engrafted. The cumulative relapse incidence was 39% at a median follow-up of 22 months (range: 4-49) for all patients. The median time to relapse was 6.4 months (range: 2.5-19). The cumulative rate of relapse was 89% in the MC group and 6% in the CC group with a median follow-up of 21 and 32 months, respectively, when CCA was applied. Nonrelapse mortality occurred in 12/67 (18%) patients with MC detected with any method and 21/101 (21%) CC patients (NS). In all, 33 patients died 4day þ 100 due to causes unrelated to relapse, 18 due to GVHD, 11 of infections, one of pulmonary embolism and three of respiratory failure. As of November 30, 2004 , patients with MC detected at any time and not relapsing (n ¼ 8) had a follow-up of 15 months (range: [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . At the time of MC detection, all patients were in complete hematological remission. All MC patients were complete donor chimera prior to the observation of MC. Mean intervals of chimerism testing were 24 days (range: 11-116).
Purity of immunomagnetic selection
Purity of the CD3 þ -and CD34 þ -beaded cell fraction was assayed by flow cytometry. In total, 18 patients (11%) had to be excluded because of a subset purity below 90%. Mean purity of the positive-selected CD34 þ cell fraction was 97% (range: 93-99%), while the negative fraction obtained after two cycles of positive selection contained a median of 1.9% (range: 0.2-2.3%) CD34 þ cells. Screening for an aberrant leukemia immunophenotype in combination with the absence of CD34 was negative, and therefore separation of CD34 þ cells was performed in all samples. Mean purity of the positive-selected CD3 þ cell fraction was 93% (range: 91-97%), while the negative fraction obtained after two cycles of positive selection contained a median of 5.4% (range: 0.5-15%) CD3 þ cells.
Association of chimerism analysis and relapse
LCA and relapse
Mixed chimerism in PB and/or BM X30 days after aHCT, in cell-separated CD34 þ lineages, was detected in 66 AML patients at least 10 days prior to clinical relapse. In all, 59 of these patients (89%) subsequently relapsed as compared to 6/102 patients (6%) with a complete donor chimerism (CC) which relapsed. In all those with a verified relapse after aHCT, the CD34 immunophenotype employed for chimerism analysis was expressed by the leukemic clone at the time of relapse.
MC in relapse patients was detected in BM (n ¼ 12) only, BM and PB (n ¼ 28) and PB (n ¼ 19) samples, respectively. The fact that PB samples were more frequently investigated as compared to BM precludes a direct comparison of the diagnostic value of both specimens. The observation that in 12 relapse patients MC Immunomodulation based on chimerism analysis in myeloid malignancies R Zeiser et al was already detectable in BM, while PB demonstrated CC is in line with the clinical experience that hematological relapse is often detectable earlier in BM than in PB. In four patients, in whom MC was detected after the clinical diagnosis of relapse, no sample was available for more than 2.5 months for chimerism analysis. These transitory enlarged intervals prior to relapse included 2.5, 2.9, 3.1 and 3.4 months in the individual patient and were due to patients wish. One patient with a CC relapsed from an extramedullary side (breast) without BM involvement. In this patient, no MC and no leukemic cells were detected in BM at the time of relapse. The eight patients still in CR, with stable MC after day þ 30, showed only MC in BM (n ¼ 6) or in PB and BM (n ¼ 2). Five patients converted to CC after withdrawal of immunosuppression and three patients after pre-emptive DLI. As of November 30, 2004 , patients with MC detected at any time and not relapsing (n ¼ 8) had a follow-up of 6.2 months (range: 4.6-11). Two MC patients have died of GVHD without any evidence for hematological relapse. Both patients had received preemptive DLI and achieved CC.
CCA and relapse
Mixed chimerism in PB and/or BM X30 days after aHCT, in unseparated MNC, was detected in 67 AML patients at least 12 days prior to clinical relapse. In all, 55 of these patients subsequently relapsed as compared to 10/101 CC patients who relapsed. Of these 10 patients, four kept their regular intervals of monthly testing, while the six others had increased the interval preceding hematological relapse to: 2.5, 2.9, 3.1, 3.4, 3.6 and 3.7 months, resulting in a median interval for chimerism analysis of 2.7 months for all 10 relapse patients. The chimerism testing frequency for the individual patient is detailed in Table 2 .
Comparison of LCA and CCA MC was detected at a median of 28 (12-54) and 30 (12-61) days before clinical relapse by CCA and LCA, respectively (P40.05).
The patient groups stratified according to the detection of MC by CCA vs LCA overlapped in 61 MC patients. At 89% (CI: 64-96%), LCA reached a comparable sensitivity to CCA (87%; CI: 61-94%). There was also no significant difference in specificity when comparing LCA with CCA (96 vs 94%, NS).
Conditioning regimen and chimerism status
Complete donor chimerism (CC) on day þ 30 post-HCT was achieved in 91/95 (96%) and 73/73 (100%) patients who received FBM and BU/CY conditioning, respectively (NS). Late MC (4day þ 100) without any evidence of relapse was seen in 5/95 (5%) and 3/73 (4%) patients receiving FBM and BU/CY conditioning, respectively (NS). Therefore, autologous hematopoiesis had a comparable frequency in the FBM and the BU/CY patient groups.
Pre-emptive immunemodulation in relapsing patients
In all, 21 relapse patients were under immunosuppression when MC was detected and discontinuation of CSA or MMF was the front-line treatment. DLIs were administered to 29 patients with increasing MC and to three patients with stable MC. DLI treatment and alternative therapies are depicted in Table 3 . Mean T-cell dose was 3.2 Â 10 6 and ranged from 4. 
Quantitative chimerism monitoring
Continuous CC was observed in 101 patients, 67 patients had either increasing (n ¼ 54) or stable (n ¼ 13) MC prior to any therapeutic intervention. No spontaneously decreasing MC was observed. At the time of MC detection, all patients were in complete hematological remission. Of the 32 patients who were i The first MC was detected in BM (n ¼ 12). j Chimerism testing intervals were transitory enlarged (n ¼ 8). k MC was detected by LCA only (n ¼ 4). l MC was detected at the same time point as hematological relapse (n ¼ 6) by LCA and CCA. In these patients, no chimerism kinetic monitoring was performed. UPN 718 relapsed from an extramedullary site without MC. Bold letters: CCA and LCA detect MC at different time points (n ¼ 4). Immunomodulation based on chimerism analysis in myeloid malignancies R Zeiser et al offered DLI7IL-2/IFN-a, 10 patients achieved at least transitory CC. Eight of 21 patients (38%) showed a conversion to CC after the discontinuation of CSA or MMF. All patients with an increasing MC relapsed later. Response to withdrawal of immunosuppression was with a medium time to response of 1.5 weeks faster than response to DLI with 2.7 weeks. No significant difference in response to DLI with respect to the coadministration of IL-2 or IFN-a was observed. LL-MC was detected in eight patients (8/13 patients with stable MC). At a median follow-up of 6.2 months (range: 4.6-11), all LL-MC patients are in complete hematological remission. Five patients with stable MC, not fulfilling the criteria of LL-MC, relapsed.
Chimerism status within CD3
þ separated cells
Mixed chimerism in CD3 þ cells at any given time after aHCT was detected in 39/168 (23%) patients (data not shown). Nine of the 65 patients (14%) who subsequently relapsed showed T-cell MC at any time after aHCT as compared to 30/103 (30%) in CR (NS). Of the three patients with a late relapse (410 months after aHCT), none showed T-cell MC. The occurrence of a T-cell MC was not associated with acute and chronic GVHD (Xgrade 2), which was observed in 68 (40%) and 34 (20%) patients, respectively.
Discussion
Adoptive immunotherapy by DLI has been significantly more successful in the treatment of relapse in patients with CML as compared to those with acute leukemia. 24 It is also known that in CML patients with a relapse after aHCT, the success of DLI is related to the tumor burden. 7 This observation may be partly explained by the more rapidly evolving tumor burden in acute as compared to chronic leukemia. Since there is a close relationship between the tumor burden and the likelihood of curing acute leukemia, it is important to develop sensitive and specific techniques that will allow for early detection of a leukemia relapse after aHCT. 25 In order to detect MRD after aHCT in patients with AML and MDS, PCR of translocation breakpoints has been employed. 26, 27 Unfortunately, this method is applicable in only a fraction (20-30%) of AML patients. 28 Chimerism analysis, which can be used in almost all patients, may therefore be an alternative for the early detection of recurrence of malignant disease after aHCT. Since a constantly low MC has been shown not to correlate with relapse, there is still a debate whether chimerism analysis is applicable as an indicator for MRD and relapse. [29] [30] [31] This may be explained by long time intervals between chimerism monitoring after aHCT, increasing the risk of missing a rapidly evolving MC before hematological relapse. Bader et al 4, 31, 32 demonstrated that MC was predictive for a relapse when samples were taken at shorter intervals after aHCT. Beside the shortening of chimerism monitoring intervals to increase the sensitivity and specificity of chimerism analysis, the investigation of enriched cell populations expected to contain the malignant clone is under investigation. Several study groups have previously demonstrated that the use of lineage-specific markers can increase the sensitivity of chimerism analysis in comparison to morphological BME only. [11] [12] [13] [33] [34] [35] [36] Zetterquist et al 33 have demonstrated that by reducing the irrelevant background, the sensitivity of chimerism analysis is significantly increased when CD19 þ cells are analyzed separately in patients with pre-B-ALL and B-CLL after aHCT. Thiede et al 13 have observed that high sensitivity may be achieved after cell separation of CD34 þ , cells even in PB samples, thus enabling early detection of leukemia relapse after aHCT.
In this study, we aimed to compare LCA and CCA with respect to the risk that the patient would develop a clinical relapse during the post-transplant follow-up. The observation that in almost all patients CD34 could be used as a leukemiaspecific marker is in line with reported data, indicating that the CD34 marker is expressed by almost all AML subtypes according to FAB. 37 Routine feasibility of subset-specific analysis at our institution was initially hampered by the lack of subset samples with a purity 490%. This would indicate a potential problem for the LCA method, especially in patients with low leukocyte counts. However, improved automated cell sorting lead to higher cell numbers with a mean purity of the positive-selected CD3 and CD34 fractions of 93 and 97%, respectively.
LCA detected a mixed chimerism in PB and/or BM in 66 AML patients. In four patients in whom MC was detected after the clinical diagnosis of relapse, no sample was available for partly more than 2.5 months for chimerism analysis, suggesting that a transitionally evolving MC may have been missed. This observation indicates the importance of short interval chimerism monitoring in high-risk patients. In the EMR patient, no MC and no leukemic cells were detected in BM at the time of relapse. This observation corresponds to reports of ALL patients having more frequent EMR, where MRD analysis of BM is also unreliable for predicting such extramedullary manifestation of Response was defined as a return to complete donor chimerism (CC) in at least two independent tests.
Immunomodulation based on chimerism analysis in myeloid malignancies R Zeiser et al the leukemia. 38 Therefore, EMR is a potential problem with chimerism monitoring and must be considered in suggestive clinical courses.
MC in BM without any evidence of a relapse suggests residual recipient hematopoiesis. Another possible explanation for the MC that was exclusively seen in the BM might be contamination of normal recipient-derived stromal cells within the BM material, which have been shown to remain exclusively of recipient origin after aHCT. 39 The observation that none of the eight patients with a stable LL-MC relapsed suggest that in these patients close monitoring could be sufficient. However, since these patients received either pre-emptive DLI (38%) or withdrawal of immunosuppression (62%) was performed, it is not clear whether they might have relapsed without such treatment. Therefore, the decision on therapeutical intervention in our institution is not based on a specific cutoff of host chimerism but on chimerism kinetics. Our data indicate that an increasing MC needs immediate therapeutical intervention.
Treatment of MC by withdrawal of immunosuppression and DLI was followed by comparable CC rates. The observation that time to response was faster in the patient group undergoing cessation of immunosuppression as compared to the DLI group is in line with the experience of Bader et al 32 in children with acute lymphoblastic leukemia. A possible explanation for the delayed response to DLI may be the time to clonal expansion required for the adoptively transferred T cells.
The frustrating observation that all patients with increasing MC relapsed despite DLI treatment (54%) or withdrawal of immune suppression (24%) indicates the necessity of developing novel strategies to deal with the rapidly evolving relapse in AML patients. Shorter chimerism intervals as compared to our median interval of 24 days may improve responsiveness to immunomodulatory treatment. Shortening of chimerism monitoring intervals to 1 week during the first 100 days post-aHCT has been proven to be effective in childhood ALL, 32 and therefore may be also of benefit in adult AML patients. Furthermore, higher T-cell doses in patients with increasing MC receiving DLI may allow for an enhanced GVL effect. Mean DLI T-cell dose in our patients was 3.2 Â 10 6 CD3 þ /kg bodyweight and the feasibility of CD3 þ doses of 19 Â 10 6 CD3 þ /kg bodyweight has been shown. 40 Overall, we could not detect significant differences between LCA and CCA with respect to sensitivity and specificity in the routine application of both methods in AML and MDS patients undergoing myeloablative conditioning.
The majority of our study patients (88%) followed the regular chimerism testing intervals making a bias due to uneven testing unlikely. However, we cannot exclude the possibility that with shorter chimerism monitoring intervals (below 1 month in standard risk and below 2 weeks in high-risk AML patients), the higher in vitro sensitivity of LCA would translate into a clinically relevant advantage.
LCA had a 20-to 30-fold higher sensitivity in vitro and should therefore provide earlier evidence of MC. Since we could not detect such higher sensitivity, a possible explanation may be that the onset of relapse in AML is so rapid that the higher in vitro sensitivity of LCA permitting detection of expanding autologous cells is not big enough to translate into temporally relevant advantage in relapse prediction.
Further studies are needed to clarify whether shortening of chimerism monitoring intervals to deal with rapidly evolving relapse in adult AML patients can improve the impact of immunomodulatory treatment.
